|
|
|
|
LEADER |
00000cam a2200000 i 4500 |
001 |
SCIDIR_ocn894117832 |
003 |
OCoLC |
005 |
20231120111851.0 |
006 |
m o d |
007 |
cr cnu---unuuu |
008 |
141031s1967 nyua obi 001 0 eng d |
040 |
|
|
|a OPELS
|b eng
|e rda
|e pn
|c OPELS
|d E7B
|d OCLCQ
|d OCLCA
|d VLY
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCL
|
020 |
|
|
|z 9781483230269
|
020 |
|
|
|z 1483230260
|
035 |
|
|
|a (OCoLC)894117832
|
050 |
|
4 |
|a RM315
|
082 |
0 |
4 |
|a 615.7/88
|2 23
|
245 |
0 |
0 |
|a Psychopharmacological agents.
|n Volume II /
|c edited by Maxwell Gordon.
|
264 |
|
1 |
|a New York :
|b Academic Press,
|c 1967.
|
300 |
|
|
|a 1 online resource :
|b illustrations
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
1 |
|
|a Medicinal chemistry ;
|v volume 4, Part B
|
504 |
|
|
|a Includes bibliographical references and indexes.
|
588 |
0 |
|
|a Print version record.
|
505 |
0 |
|
|a Front Cover; Psychopharmacological Agents; Copyright Page; Dedication; List of Contributors; Foreword; Preface to Volume I; Preface to Volume II; Table of Contents; Contents of Volume I; Chapter 1. Phenothiazines; I. INTRODUCTION; II. SYNTHESIS OF THE PHENOTHIAZINES; III. SOME PROCEDURES FOR THE PHARMACOLOGICAL EVALUATION OF PSYCHOPHARMACOLOGICAL AGENTS; IV. PHARMACOLOGY OF CHLORPROMAZINE; V. STRUCTURE-ACTIVITY RELATIONSHIPS IN THE PHENOTHIAZINES; VI. In Vivo DISTRIBUTION AND METABOLISM OF PHENOTHIAZINES; VII. ANALYTICAL METHODS FOR PHENOTHIAZINES
|
505 |
8 |
|
|a VIII. MISCELLANEOUS PROPERTIES OF PHENOTHIAZINESIX. SUMMARY OF CLINICAL APPLICATIONS; REFERENCES; Chapter 2. Haloperidol and Related Butyrophenones; I. ORIGIN; II. STRUCTURE-ACTIVITY RELATIONSHIPS; III. PHARMACOLOGICAL ACTIVITY OF THE BUTYROPHENONES; IV. CLINICAL USES; REFERENCES; Chapter 3. Biochemical Basis of Mental Disease; I. INTRODUCTION; II. THEORIES OF MENTAL DISEASE; REFERENCES; Chapter 4. Miscellaneous Psychotherapeutic Agents; Text; REFERENCES; Appendix A: Phenothiazine Bibliographies; A.1 Acetophenazine; A.2 Carphenazine; A.3 Fluphenazine; A.4 Mepazine; A.5 Methdilazone
|
505 |
8 |
|
|a A.6 MethoxypromazineA. 7 Perphenazine; A.8 Pipamazine; A.9 Prochlorperazine; A.10 Promazine; A.11 Propiomazine; A.12 Prothipendyl; A.13 Thiethylperazine; A.14 Thiopropazate; A.15 Thioridazine; A.16 Trifluoperazine; A.17 Triflupromazine; A.18 Trimeprazine; Appendix B: Meprobamate-like Agents Bibliographies; B.1 Phenaglycodol; B.2 Mephenoxalone; B.3 Promoxalone; B.4 Emylcamate; B.5 Hydroxyphenamate; B.6 Phenylpropanolcarbamate; B.7 Metaxalone; B.8 Methocarbamol; B.9 Oxanamide; B.10 Ectylurea; B.11 Methyprylone; B.12 Ethchlorvynol; Appendix C: Addenda to Volume I; C.1 Chlorprothixene
|
505 |
8 |
|
|a C.2 Clinical Applications of the Monoamine Oxidase Inhibitors (Hydrazines): AddendumC. 3 Biochemistry and Pharmacology of the Monoamine Oxidase Inhibitors (Hydrazines): Addendum; Author Index; Subject Index
|
520 |
|
|
|a Psychopharmacological Agents, Volume II, provides an overview of the state of knowledge in psychopharmacological agents. The organization of this book is generally based on a treatment of the major classes of psychopharmacological agents in separate chapters. To the extent allowed by the diverse nature of the subject matter, each chapter covers the history, synthesis, pharmacological activity, in vivo distribution and metabolic fate, analytical methods, and, briefly, the clinical uses of each class of psychopharmacological agents. This volume includes a chapter on the butyrophenones, one on m.
|
650 |
|
0 |
|a Psychotropic drugs.
|
650 |
|
0 |
|a Psychopharmacology.
|
650 |
|
0 |
|a Drugs
|x Physiological effect.
|
650 |
|
2 |
|a Psychopharmacology
|0 (DNLM)D011600
|
650 |
|
2 |
|a Psychotropic Drugs
|0 (DNLM)D011619
|
650 |
|
6 |
|a Psychopharmacologie.
|0 (CaQQLa)201-0020955
|
650 |
|
6 |
|a M�edicaments
|x Effets physiologiques.
|0 (CaQQLa)201-0005070
|
650 |
|
6 |
|a Psychotropes.
|0 (CaQQLa)201-0001454
|
650 |
|
7 |
|a Psychopharmacology.
|2 fast
|0 (OCoLC)fst01081659
|
650 |
|
7 |
|a Drugs
|x Physiological effect.
|2 fast
|0 (OCoLC)fst00898862
|
650 |
|
7 |
|a Psychotropic drugs.
|2 fast
|0 (OCoLC)fst01081826
|
650 |
|
7 |
|a Psychopharmacologie.
|2 fmesh
|
655 |
|
7 |
|a Indexes.
|2 fast
|0 (OCoLC)fst01423761
|
655 |
|
2 |
|a Index
|0 (DNLM)D020481
|
655 |
|
7 |
|a indexes (reference sources)
|2 aat
|0 (CStmoGRI)aatgf300026554
|
655 |
|
7 |
|a Indexes.
|2 lcgft
|
655 |
|
7 |
|a Index.
|2 rvmgf
|0 (CaQQLa)RVMGF-000001208
|
700 |
1 |
|
|a Gordon, Maxwell,
|d 1921-
|e editor.
|
776 |
0 |
8 |
|i Print version:
|a Gordon, Maxwell, 1921- ed.
|t Psychopharmacological agents
|z 0122905598
|w (DLC) 64017794
|w (OCoLC)803871
|
830 |
|
0 |
|a Medicinal chemistry (Academic Press) ;
|v v. 4, pt. B.
|
856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9781483230269
|z Texto completo
|